Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elecoglipron versus placebo in adults with HFpEF or HFmrEF
CTR20263617Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elecoglipron in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF), sponsored by AstraZeneca. Started Sep 2026; status: active.
02
Drugs
elecoglipron
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on CTR20263617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263617.